GlassScriptPhysician profile
Joaquin De Rojas
NPI 1619387370
$160,975.07
in general payments reported to CMS, 2019-2025
30 companies · $55K in 2025
The $55K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $379 · 2021: $29K · 2022: $15K · 2023: $23K · 2024: $38K · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $69K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $12K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,355 · Travel and Lodging: $1,996 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $69,487.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,052.50 |
| Food and Beverage | $12,343.01 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,355.00 |
| Travel and Lodging | $1,995.63 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $65,897.01 | 2020-2025 | Cequa |
| Lensar, INC. | $32,493.98 | 2023-2025 | Lensar Laser System |
| Johnson & Johnson Surgical Vision, INC. | $21,812.55 | 2019-2025 | Tecnis Iol, Tecnis Iol, Veritas Vision System |
| Carl Zeiss Meditec, INC. | $12,515.05 | 2023-2025 | Veracity Surgical, Iolmaster 700, Artevo 800 |
| Nordic Pharma, INC. | $11,908.52 | 2024-2025 | Lacrifill, Lacrifill |
| Abbvie INC. | $5,323.50 | 2022-2025 | Durysta, Vuity |
| Rxsight INC | $3,503.23 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Alcon Vision LLC | $2,486.92 | 2019-2025 | Clareon, Eysuvis, Hydrus Microstent |
| Tearlab Corp | $1,121.16 | 2021 | |
| Bausch & Lomb Americas INC. | $873.15 | 2022-2025 | Miebo, Scoutpro Osmolarity System, Xiidra |
| Tarsus Pharmaceuticals, INC. | $487.38 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $429.47 | 2020-2025 | Oxervate |
| Harrow Eye, LLC | $399.43 | 2024-2025 | Vevye, Iheezo |
| Glaukos Corporation | $361.79 | 2019-2025 | Ce-Marked Kxla System, Idose, Istent Infinite |
| Allergan, INC. | $231.73 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $188.21 | 2022-2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $172.70 | 2021-2023 | |
| Amgen INC. | $122.94 | 2024 | Tepezza |
| Apellis Pharmaceuticals, INC. | $106.49 | 2023 | Syfovre |
| Sight Sciences, INC. | $103.64 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Ocular Therapeutix, INC. | $96.59 | 2021-2025 | Dextenza |
| Dutch Ophthalmic, USA | $87.43 | 2023-2024 | Tissueblue, Eva, Combined Machine |
| Johnson & Johnson Vision Care, INC. | $54.81 | 2023 | Mentor Siltex Round Spectrum |
| Halozyme INC | $45.97 | 2022-2023 | |
| Carl Zeiss Meditec USA, INC. | $35.23 | 2021 | |
| Mallinckrodt Hospital Products INC. | $25.52 | 2022 | |
| Biotissue Holdings INC. | $25.00 | 2025 | |
| Beaver-Visitec International, INC. | $24.73 | 2025 | |
| Kala Pharmaceuticals, INC. | $23.47 | 2022 | |
| Oasis Medical, INC. | $17.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joaquin De Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.